Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 2, 2019--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2018 at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.
A live webcast of Ironwood’s presentation and the question and answer session will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.
About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Our pipeline priorities for linaclotide include a Phase IIIb trial evaluating its efficacy and safety on multiple abdominal symptoms, including abdominal bloating, pain, and discomfort in adult patients with IBS-C, as well as research into a formulation of linaclotide designed to relieve pain across all IBS subtypes.
We are also advancing a pipeline of innovative product candidates in areas of significant unmet need, including persistent gastroesophageal reflux disease, diabetic nephropathy, heart failure with preserved ejection fraction and sickle cell disease. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005605/en/
CONTACT: Investor and Media Relations
Meredith Kaya, 617-374-5082
Vice President, Investor Relations and Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Ironwood Pharmaceuticals, Inc.
Copyright Business Wire 2019.
PUB: 01/02/2019 05:00 PM/DISC: 01/02/2019 05:01 PM